Ki-67/MIB-1 is the most widely used immumohistochemical marker to measure cell proliferation in recent years, and its high expression is significantly related to high malignancy and short survival cycle. This meta-analysis was conducted to confirm the prognostic value of Ki-67/MIB-1 in meningioma patients. A comprehensive search was carried out of mainstream electronic databases including Pubmed, EMBASE, Google Scholar, Web of Science, and Cochrane Library, and finally 10 studies containing 1,414 meningioma patients were included in the meta-analysis. The combined hazard ratio (HR) and its 95% confident intervals (CIs) were used to evaluate the association between Ki-67/MIB-1 expression and survival. High expression of Ki-67/MIB-1 was found to be significantly associated with low RFS (HR 3.31, 95% CI 1.62-6.78, P = 0.001, random effect) and PFS(HR 3.14, 95% CI 1.64-6.00, P = 0.001, fixed effect). Subgroup analysis was conducted to explore the potential heterogeneity. Results of the meta-analysis indicated that high expression of Ki-67/MIB-1 may serve as a useful biomarker for poor prognosis in meningioma patients.

中文翻译：

---

Ki-67 / MIB-1表达在脑膜瘤患者中的预后价值：一项荟萃分析。

Ki-67 / MIB-1是近年来测量细胞增殖最广泛使用的免疫组织化学标记物，其高表达与高恶性和短生存期显着相关。进行这项荟萃分析，以确认Ki-67 / MIB-1在脑膜瘤患者中的预后价值。对主流电子数据库（包括Pubmed，EMBASE，Google Scholar，Web of Science和Cochrane Library）进行了全面搜索，荟萃分析最终纳入了包含1,414名脑膜瘤患者的10项研究。组合危险比（HR）及其95％置信区间（CIs）用于评估Ki-67 / MIB-1表达与生存之间的关联。发现Ki-67 / MIB-1的高表达与低RFS显着相关（HR 3.31，95％CI 1.62-6.78，P = 0.001，随机效应）和PFS（HR 3.14，95％CI 1.64-6.00，P = 0.001，固定效应）。进行了亚组分析以探索潜在的异质性。荟萃分析的结果表明，Ki-67 / MIB-1的高表达可能是脑膜瘤患者预后不良的有用生物标志物。